门德尔随机化与实验验证相结合,在多发性骨髓瘤免疫反应中确定了预后基因LMNB1和PLXNB2

Xiaofen Zhang1, Qiuhong Kong2, Jianhao Zhao1

  • 1Hematology Department, The Second Affiliated Hospital of Shandong First Medical University, Taian, China.

概括

PLXNB2和LMNB1是多发性骨髓瘤 (MM) 中的主要免疫调节基因. 较低的PLXNB2和较高的LMNB1与预后不佳和免疫逃避相关,这表明它们是MM的潜在治疗点.

相关概念视频